Over the last couple of weeks we added a number of new BDC positions to our Income Portfolios despite a fairly expensive credit market backdrop. We discuss the reasons behind this and where we see ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

Barings BDC, Inc., a traded fund, seeks investment opportunities in middle-market companies located in the United States with an EBITDA ranging from $5 - $75 million and revenues between $20 and $ ...

This week’s quarterly results from Merck looked pretty good, all things considered: Sales and earnings came in ahead of Wall ...

The RIT Battery Development Center (BDC) is a state-of-the-art research and rapid prototyping and testing facility focused on the development and qualification of emerging energy storage technologies ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Merck lowered 2024 EPS guidance down to $7.94 to $8.03, from its previous guidance of $8.53 to $8.65. The new guidance reflects the negative impact of a one-time charge of $1.3 billion or 51 cents ...

Investors in Barings BDC, Inc. (NYSE: BBDC) need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 19, 2024 $12.50 Put had some of the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Despite concentration risks, Putnam BDC Income ETF provides diversification for investors unwilling to cherry-pick individual BDCs, reducing single-security risk. PBDC's top holdings include high ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

This marks Keytruda's first approval for the given indication. Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.